Via, M. A., Chandra, H., Araki, T., & al, e. (2010). Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Dove Medical Press.
Chicago Style (17th ed.) CitationVia, Michael A., Himani Chandra, Takako Araki, and et al. Bromocriptine Approved as the First Medication to Target Dopamine Activity to Improve Glycemic Control in Patients with Type 2 Diabetes. Dove Medical Press, 2010.
MLA (8th ed.) CitationVia, Michael A., et al. Bromocriptine Approved as the First Medication to Target Dopamine Activity to Improve Glycemic Control in Patients with Type 2 Diabetes. Dove Medical Press, 2010.
Warning: These citations may not always be 100% accurate.